Company profile
Synthace: the Life Science Experiment Platform for R&D teams
The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
Updated 06 Jun 2026 16:52
Financial period: 1 Feb 2023 to 31 Jan 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
SH01 | Transaction MzQ5NDUzMjQxMmFkaXF6a2N4 | Paper/PDF filed
Published 08 Apr 2026 22:46
Last confirmation statement made up date
SH01 | Transaction MzQ1NTgzMjMzOGFkaXF6a2N4
Published 20 Feb 2025 02:27
Last accounts made up date
TM01 | Transaction MzQ0MTQ1OTQxNWFkaXF6a2N4
Published 31 Oct 2024 01:08
SH01 | Transaction MzQzODYxNzk5N2FkaXF6a2N4
Published 07 Oct 2024 07:54
Company registered at Companies House
Synthace produces high value, bio-based chemical and biological products through the application of synthetic biology. They are able to rapidly engineer and optimise novel biological production systems. This is achieved through the integration of computational modelling and big data analysis with wet lab experimental design and innovative molecular biology tools. Their bioengineering platform is broadly applicable across multiple industry sectors, including the production of specialty chemicals from renewable feedstocks using efficient and sustainable processes.
Synthace develops cloud software for the life sciences industry, allowing R&D organisations to automate experiments and collate data and insights.
Awarded ?500,000 TSB Synthetic Biology Grant in 2013.
1 Dec 2017 to 31 Jan 2020
Cell and gene therapies offer unprecedented promise for the cure, treatment or long term management of disease. However, the challenge facing the industry is the need for viral vectors which can be consistently manufactured to commercial scale with rigorous tolerances for purity, potency and safety. This collaboration to support advanced therapies is led ...
1 Aug 2014 to 31 Oct 2015
The bioscience industry currently relies on a small number of organisms to produce the majority of the recombinant products on the market. A collaboration between two UK synthetic biology Synthace and Synpromics and University College London, this project combines cutting edge computational techniques with multifactorial experimental design to develop a n...
1 Jun 2013 to 30 Nov 2014
This project will integrate a number of novel synthetic biology technologies in a demonstration project to rapidly engineer a cellular factory. This includes a novel biopump from UCL which will allow the selective import of a hydrophobic substrate into the cell, where a short synthetic pathway will transform it into a higher value aroma chemical, before t...
